Oct 20- NewLink Genetics Corp said it entered into a licensing agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments. NewLink's shares jumped nearly 26 percent before the bell on Monday. Immunotherapies are a class of drugs designed to help the...» Read More
*Sanofi, MannKind aim to launch Afrezza in U.S. in Q1 2015. PARIS/ LONDON, Aug 11- French drugmaker Sanofi is betting on inhaled insulin as an alternative option to daily injections for diabetics by signing a worldwide licensing agreement with MannKind Corp worth up to $925 million.